Ipv Vaccines Market

Inactivated polio vaccine (IPV) is also known as Salk vaccine. For the vaccination against polio there are two vaccines available: inactivated polio vaccine and oral polio vaccine. The IPV vaccine is mostly given in arm or leg as a shot.

Individuals who are allergic to eggs or the drugs such as streptomycin should not receive the injectable IPV. The IPV is only given if the vaccine recipient is on steroid therapy for long-term, has cancer, or is on ongoing process of chemotherapy or there is any unimmunized adult in house.

Global IPV vaccines market was valued at USD 199.6 Mn in 2024 and is expected to increase to US$ 352.4 Mn by 2031, registering a CAGR of 8.5% over the forecast period.

Market Dynamics

Various governments have taken initiatives to increase awareness regarding vaccination to prevent occurrence of polio among the population. Public introduced beneficial immunization programs to provide vaccination to poor people, which is expected to create a highly conducive environment for growth of the Global Inactivated Polio Vaccines Market (IPV) in the near future. For instance, in September 2019, the Ghana Health Service (GHS), launched series of polio vaccination/immunization campaign to prevent spreading of the virus in high risk areas. The immunization polio vaccination campaign will use the inactivated polio vaccine (IPV) to immunize all the children born from January 2016 to June 2018 in all districts across Ghana.

Key features of the study:

• This report provides in-depth analysis of the Global IPV vaccines market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Global IPV vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The IPV vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global IPV vaccines market

Detailed Segmentation:

• Global IPV Vaccines Market, by Vaccine Brand:
  • Poliovac (Pfs/Sd)
  • Shanipv
  • Poliorix
  • Ipol/Imovax
  • Polymilex
• Global IPV Vaccines Market, by Distribution Channel:
  • Private
  • Public
• Global IPV Vaccines Market, by Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles:
• • GlaxoSmithKline Plc*
    • Company highlights
    • Product Portfolio
    • Key Highlights
    • Financial performance
    • Strategies
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • PT Bio Farma
  • AJ Vaccines

“*” marked represents similar segmentation in other categories in the respective section.